
Original Contributions

EFFICACY OF INTRANASAL NALOXONE AS A NEEDLELESS ALTERNATIVE FOR TREATMENT OF OPIOID OVERDOSE IN THE PREHOSPITAL SETTING

Erik D. Barton, MD, MS,* Christopher B. Colwell, MD,† Timothy Wolfe, MD,* Dave Fosnocht, MD,*
Craig Gravitz, EMT-P,† Tamara Bryan, EMT-P,† Will Dunn, EMT-P,† Jeff Benson, EMT-P,† and
Jeff Bailey, EMT-P†

*Division of Emergency Medicine, Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah and
†Department of Emergency Medicine and Denver Paramedic Division, Denver Health Medical Center, Denver, Colorado
Reprint Address: Erik D. Barton, MD, MS, University of Utah, Division of Emergency Medicine, 175 North Medical Drive East,
1150 Moran Building, Salt Lake City, UT 84132

□ **Abstract**—Prehospital providers are at increased risk for blood-borne exposure and disease due to the nature of their environment. The use of intranasal (i.n.) medications in high-risk populations may limit this risk of exposure. To determine the efficacy of i.n. naloxone in the treatment of suspected opiate overdose patients in the prehospital setting, a prospective, nonrandomized trial of administering i.n. naloxone by paramedics to patients with suspected opiate overdoses over a 6-month period was performed. All adult patients encountered in the prehospital setting as suspected opiate overdose (OD), found down (FD), or with altered mental status (AMS) who met the criteria for naloxone administration were included in the study. i.n. naloxone (2 mg) was administered immediately upon patient contact and before i.v. insertion and administration of i.v. naloxone (2 mg). Patients were then treated by EMS protocol. The main outcome measures were: time of i.n. naloxone administration, time of i.v. naloxone administration, time of appropriate patient response as reported by paramedics. Ninety-five patients received i.n. naloxone and were included in the study. A total of 52 patients responded to naloxone by either i.n. or i.v., with 43 (83%) responding to i.n. naloxone alone. Seven patients (16%) in this group required further doses of i.v. naloxone. In conclusion, i.n.

naloxone is a novel alternative method for drug administration in high-risk patients in the prehospital setting with good overall effectiveness. The use of this route is further discussed in relation to efficacy of treatment and minimizing the risk of blood-borne exposures to EMS personnel. © 2005 Elsevier Inc.

□ **Keywords**—Prehospital; intranasal; naloxone; overdose; exposure; needlestick

INTRODUCTION

In 1991, the Occupational Safety and Health Administration (OSHA) published the Occupational Exposure to Bloodborne Pathogens standard. This regulation outlines employer requirements necessary for the implementation of an exposure control plan to reduce or eliminate hazards from bloodborne pathogens and infectious materials (1). The regulation specifically targets engineering controls as a primary means of eliminating or minimizing employee exposures. These controls include implementation of safer medical devices such as needleless systems and shielded needles. Despite advances in medical device technology that reduce needlestick risk, employee exposures continue to be of concern. Frequency of these

Dr. Wolfe is the Vice president and Medical Director of Wolfe Tory Medical, Inc, the company that supplied the Mucosal Atomizer Devices (MAD[®]) for the study.

RECEIVED: 7 July 2004; FINAL SUBMISSION RECEIVED: 19 January 2005;
ACCEPTED: 21 March 2005

exposures remains high, and the potential long-term mental and physical health effects can be severe (2–5).

In response to the continued prevalence of bloodborne pathogen exposures from accidental sharps injuries in the workplace, OSHA developed The Needlestick Safety and Prevention Act (Pub. L. 106-430), which was signed into law in November 2000 and became effective in April 2001 (6). It set forth in greater detail the requirements for employers to identify, evaluate, and implement safer medical devices.

Most recently, needleless technology has been implemented in hospitals, clinics, and other healthcare offices. To date, however, very few needleless systems are being used in the prehospital setting. Ambulances, including air and ground programs, rarely find one needleless system that has universal compatibility with the various devices used in the hospitals they service. For this reason, most prehospital providers still rely on needle-type devices to access peripheral intravenous (i.v.) lines and to administer subcutaneous (s.q.), and intramuscular (i.m.) medications.

Intranasal (i.n.) medication delivery is an alternate delivery route for injectable medications. When used with carefully selected medications, this delivery route has the advantage of rapid onset, high plasma bioavailability, direct transport to the central nervous system (CNS) across the olfactory mucosa, elimination of first pass metabolism and, perhaps most importantly, elimination of all needles (7–13). Access to the nose is also relatively immediate, especially in the prehospital setting where access to extremities through clothing can be highly variable from one patient to the next. Intranasal medication administration in the emergent setting is a rapid and a safe method for both the patient and the provider that has been underutilized to date.

We investigated the use of i.n. naloxone (Narcan[®]) by paramedics to assess its efficacy and safety as an alternative (needleless) medication delivery route. Narcan is commonly used in patients suffering from a suspected opioid overdose. These patients often have limited peripheral venous access, making the intranasal route potentially very advantageous. The preliminary data, published in January 2002, was very promising (14). This study reports the final data from that series and makes the recommendation that the intranasal route should be considered as a safer method of administering naloxone in high-risk patients encountered in the field. Additionally, we will briefly discuss other intranasal medications that hold promise in the prehospital setting.

METHODS

Study Design

This study was performed by the Denver Health Paramedic Division as a prospective evaluation of intranasal



Figure 1. The Mucosal Atomizer Device (MAD[®]) attached to a syringe showing the spray pattern of medication.

naloxone in all patients who presented with potential opiate drug intoxication. The study was performed from February 1 to August 30, 2001 as part of a Paramedic Division Quality Assurance Evaluation of i.n. naloxone. There was an interruption in the study (March to June) due to a national shortage of naloxone in the 2 mg/2 mL concentration doses. Data collection occurred for a total of 3 months during the study period. All paramedics went through a brief training curriculum that taught the use of the i.n. naloxone device and the appropriate documentation required before the start of the study. Institutional Review Board (IRB) approval was granted (protocol #01-635).

Procedure

All adult patients (> 14 years) encountered in the field with a prehospital encounter diagnosis of “altered mental status” (AMS), “found down” (FD), or “suspected opioid overdose” (OD) were eligible for the study. The standard protocol called for these patients to have an i.v. placed and to receive i.v. naloxone (1–2 mg) based on the paramedic’s assessment of a possible overdose. For the study this protocol was modified so that these patients initially had 2 mg of intranasal naloxone administered using a disposable Mucosal Atomizer Device (MAD[®], Wolfe-Tory Medical, Inc., Salt Lake City, UT) (Figure 1). One mL of the 1 mg/mL naloxone solution was administered into each naris by inserting the MAD[®]

November 10, 2011

approximately ¼ to ½ inch, for a total volume of 2 mL. Immediately after i.n. naloxone, the standard protocol including airway management, i.v. line placement and i.v. medications was followed. The standard protocol was discontinued only if the patient responded and no further treatment was required. Data sheets were completed for all patients (Figure 2) and included: times of initial patient encounter, i.n. naloxone administration, i.v. insertion, i.v. naloxone administration, and patient response. In addition, paramedics were asked to report any obvious abnormalities noted in the patient's nasal mucosa (such as bleeding, deformity, mucus, etc.) at the time of i.n. drug administration.

Outcomes

The number of patients responding to i.n. naloxone, defined as a significant improvement in level of consciousness as determined by paramedics, before i.v. administration of a second dose of naloxone was recorded. Additionally, the time of response to naloxone (to the nearest minute) was measured by paramedics. Results were analyzed using McNemar Change test and two-tailed *t*-tests for independent samples.

RESULTS

Ninety-five patients met study criteria and received i.n. naloxone. Fifty-two of these patients responded to either i.n. or i.v. naloxone ("Naloxone Responders"). Table 1 lists the category to which the paramedics assigned the patients and the percentage that responded to naloxone. The majority of patients (63%) were suspected of having an opiate overdose upon initial assessment by the paramedic. Three patients were assigned to two categories. Forty-three (83%) of the 52 "Naloxone Responders" ($p = 0.0011$) awoke with intranasal naloxone before the paramedics could administer the naloxone intravenously. Table 2 lists mean and median response times from paramedic arrival and from drug administration for all naloxone responders. Twelve of the 43 i.n. "Naloxone Responders" (29%) received no i.v. placement in the field after i.n. naloxone delivery. Seven patients (16%) in the i.n. naloxone response group required additional doses of i.v. naloxone after initial response due to "recurrent somnolence" or "slow response," whereas 36 patients (84%) required no further naloxone therapy (69% of all "Naloxone Responders"). None of the "Naloxone Responders" was reported to have severe withdrawal reactions from either i.v. or i.n. naloxone.

There were nine patients (17%) who responded only to i.v. naloxone and not to i.n. naloxone. Five of these

nine (56%) i.n. nonresponder patients had "epistaxis" (2), "nasal mucus" (1), "trauma" (1), or "septal abnormality" (1), as noted by paramedics. None of the i.n. naloxone responders had any nasal abnormality noted by paramedics.

DISCUSSION

With the increasing seroprevalence of bloodborne pathogens, accidental needle sticks now pose a life-changing and possibly life-ending event to health care providers. This risk is especially high in the Emergency Medical Services (EMS) environment. Marcus et al. found a human immunodeficiency virus (HIV) seroprevalence rate of 4.1 to 8.9 per 100 patient visits in three inner-city Emergency Department (ED) populations (15). The annual blood contact for an individual EMS worker has been estimated to be as high as 12.3 per year in populations where over 90% of patients' HIV status are unknown (16). There is much concern that this high exposure rate can result in viral seroconversion of EMS providers. Valenzuela et al. reported a fivefold higher prevalence of Hepatitis B (HBV) infection in paramedics than that observed in a comparable population from the same city in 1985 (17). Pepe et al. confirmed this correlation in Houston EMS personnel, noting a strong association between years of employment and the rate of HBV infections (18). Although there is less risk today with the advent of HBV vaccines and use of universal precautions, the risk for other exposures remains significant.

An especially high-risk patient population to EMS providers is the intravenous drug abuser (IVDA). These patients have HIV, HBV and Hepatitis C (HBC) seroprevalence rates that are far higher than the baseline population and the serostatus is typically unknown to EMS workers (19). In addition, EMS personnel commonly are involved in their care for life-threatening illnesses such as respiratory arrest from opiate overdose. Because opiate overdose patients rarely need an i.v. for any reason beyond the administration of naloxone (20–22), a needleless method of administering naloxone would eliminate needlestick risk and potential transmission of bloodborne pathogens.

As this study demonstrates, such a delivery method exists. Like nitroglycerine, which is rapidly absorbed across mucosal membranes, naloxone also easily crosses the mucosal membranes. After intranasal mucosal administration, naloxone exhibits opiate antagonist effects almost as rapidly as the i.v. route with a bioavailability and clinical response approaching 100% in animal and human studies (7–9). The current series is a report of routine i.n. naloxone use in the emergent setting of opiate

PREHOSPITAL INTRANASAL NARCAN

(For Quality Assurance/Performance Improvement Purposes Only)

PROTOCOL FOR DEVICE USE:

- 1) Time of first contact noted as accurately as possible.
- 2) Load syringe with 2 mg of Narcan and nasal atomizer.
- 3) Administer intranasal Narcan via rapid intranasal mist spray of 1cc to each nostril.
- 4) Time of administration accurately noted and whether patient responded.
- 5) Continue normal attempt(s) to gain IV access and secure airway as needed.
- 6) Record time of IV Narcan if given and whether patient responded.

NOTE: Protocol stops after patient response.

PATIENT DATA:

DATE: _____ TRIP #: _____

INDICATION for Narcan: Opioid overdose Altered mental status Found down

Other: _____

- 1) TIME OF FIRST PATIENT CONTACT: _____
- 2) TIME INTRANASAL NARCAN ADMINISTERED: _____
- 3) TIME IV LINE STARTED: _____
- 4) DID THE PATIENT AROUSE AFTER INTRANASAL NARCAN: Yes No
(If No, then continue with Intravenous Narcan)
- 5) TIME IV NARCAN GIVEN: __ RESPONSE: Yes No
- 6) RESPONSE TO OTHER MEDICATION: Yes (med) _____ No
- 7) TIME OF PATIENT RESPONSE: _____

NASAL abnormalities noted: Septal abnormality Epistaxis Mucous

Trauma Other: _____

COMPLICATIONS/COMMENTS: _____

***** NOTE *** PLEASE ATTACH COMPLETED FORM TO TRIP SHEET**

Figure 2. Paramedic recording sheet for Prehospital Intranasal Narcan study.

overdose. This study shows that intranasal naloxone is a clinically effective, rapid, needleless approach for administering naloxone to patients suffering an opiate over-

dose and is easily implemented in the prehospital setting. Our results demonstrate an 83% response rate to i.n. naloxone in patients suffering an opiate overdose. In

Nalox-1021

Table 1. Numbers of Patients who Presented with Altered Mental Status (AMS), Found Down (FD) or as a Suspected Opiate Overdose (OD), and the Number of Patients who Responded to Naloxone ("Naloxone Responders")

	AMS (n = 40)	FD (n = 20)	OD (n = 38)
Total patients (n = 95)			
"Naloxone responders"	11 (22%)	8 (15%)	33 (63%)

Note: three patients were listed in two categories.

actual practice, response rates to i.n. naloxone may be greater than 83%. By study design, no delays for i.v. naloxone were allowed, resulting in a number of cases where i.v. naloxone was administered shortly after i.n. naloxone due to rapid i.v. placement. Four of the nine patients (44%) reported to have responded only to i.v. naloxone received the i.v. dose within 4 min or less after the i.n. dose. Because i.n. naloxone often takes 4 min to arouse a patient, some of these patients may have responded to i.n. naloxone but were identified as nonresponders because they received i.v. naloxone within such a short time period.

When comparing time of response to i.n. naloxone to other routes of administration, it seems to be equivalent. Median times from arrival at the patient's side to clinical response (8.0 min i.n. vs. 10.0 min i.v.) and from drug administration to clinical response (3.0 min i.n. vs. 3.0 min i.v.) were not significantly different between i.n. delivery and i.v. delivery. These median times to clinical response after naloxone administration are similar to those previously reported for intravenous naloxone and subcutaneous naloxone (23). Wanger et al. found that the median time from ambulance arrival to patient response (defined at a RR > 10) was 9.3 (\pm 4.2) minutes for i.v. naloxone, and 9.6 (\pm 4.58) min for s.q. naloxone. The median times from drug administration to clinical response were 3.8 min for i.v. naloxone and 5.5 min for s.q. naloxone. The authors conclude that the delay in re-

Table 2. Intranasal (i.n.) and Intravenous (i.v.) "Naloxone Responders" in the Prehospital Setting

	Response Times in minutes (\pm SD)		
	n = 52	Initial contact	Drug administration
i.n. Naloxone	43 (83%)	9.9 (\pm 4.4) (median 8.0)	4.2 (\pm 2.7) (median 3.0)
i.v. Naloxone	9 (17%)	12.8 (\pm 7.6) (median 10.0)	3.7 (\pm 2.3) (median 3.0)
p Value	0.0011	(ns)	(ns)

Note: times reported from initial patient contact and from drug administration to observed response.

Table 3. Intranasal Medications Previously Studied for Systemic Indications [adapted from Barton, et al. (3)]

Indication	Medications
Analgesia	Fentanyl
	Diamorphine
Antiemetics	Sufentanil
	Buprenorphine
	Meclizine
	Metoclopramide
	Hydralazine
Antihypertensives	Nifedipine
	Nitroglycerine
	Propranolol
	Verapamil
	Atropine
Cardiac arrest/ACLS	Epinephrine
	Lidocaine
	Naloxone
Drug overdose	Butorphanol
	Dihydroergotamine
Headache therapy	Lidocaine
	Sumatriptan
Hypoglycemia	Dextrose
	Glucagon
Sedation	Diazepam
	Ketamine
	Midazolam
Seizures	Diazepam
	Midazolam
	Gentamycin
Miscellaneous	Gentamycin
	Neostigmine

sponse to s.q. administration was compensated for by the time it took to establish i.v. access, making the delivery routes equivalent in efficacy. We believe the same logic applies to i.n. delivery with the added safety advantage that no needle is used.

Intranasal naloxone is not the only medication holding promise for needlestick risk reduction and improved patient care in the prehospital setting. Table 3 gives a listing of a number of medications routinely used in the EMS setting that are effective when delivered intranasally. One of the most important is i.n. midazolam for seizure control. A number of studies have demonstrated that emergent seizure control with i.n. midazolam is as effective as the long-held standard of intravenous diazepam and superior to rectal diazepam (24–27). Lahat et al. found i.n. midazolam to provide equivalent control of pediatric seizures compared to i.v. diazepam (28). In addition, due to the time it took to start an i.v. in a seizing child, the i.n. midazolam group (6.1 min) had a significant reduction in total time to seizure cessation compared to the i.v. diazepam group (8 min). Fisgin et al. noted a much better control of pediatric seizures using i.n. midazolam (87% cessation) when compared to rectal diazepam (60% cessation) (24).

Transmucosal drug delivery is emerging as a promis-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.